Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377116 | 1.00 | KDM4E (0.41) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| Hydrochloric Acid SCHEMBL12492574 | 0.98 | KDM4E (0.40) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| Hydrochloric Acid SCHEMBL12492576 | 0.98 | KDM4E (0.40) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL15688389 | 0.89 | KDM4E (0.37) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL15688390 | 0.89 | KDM4E (0.37) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL15688344 | 0.87 | KDM4E (0.36) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL15688328 | 0.87 | KDM4E (0.36) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL12559551 | 0.86 | KDM4E (0.38) | KDM4ECYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL12311011 | 0.84 | FDPS (0.50) | KDM4EFDPSCYP1A2PTGS1PTGS2 | |
| SCHEMBL13681560 | 0.83 | KDM4E (0.44) | KDM4ECYP3A4ALDH1A1TDP1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756670-A | Synthesis method of rilpivirine intermediate | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | claimed |
| CN-111333543-B | Synthesis method of rilpivirine intermediate | 武汉工程大学 | 2022-09-16 | — | — | CN | claimed |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-03-17 | — | — | US | claimed |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | SHANDONG UNIVERSITY (CN) | 2020-01-30 | — | — | US | claimed |
| EP-2702044-B1 | PROCESS FOR RILPIVIRINE | HETERO RESEARCH FOUNDATION (IN) | 2017-03-22 | — | — | EP | claimed |
| EP-2643294-B1 | AN IMPROVED RILPIVIRINE PROCESS | EMCURE PHARMACEUTICALS LTD (IN) | 2016-08-24 | — | — | EP | claimed |
| US-8618291-B2 | Process for preparing 4-[(1,6-dihydro-6-OXO-2-pyrimidinyl)amino]benzonitrile | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2013-12-31 | — | — | US | claimed |
| WO-2013179105-A1 | IMPROVED PROCESS FOR PREPARATION OF RILPIVIRINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | LAURUS LABS PRIVATE LIMITED (IN) | 2013-12-05 | — | — | WO | claimed |
| CN-117756670-A | Synthesis method of rilpivirine intermediate | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756670-A | Synthesis method of rilpivirine intermediate | 苏州莱克施德药业有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-3870568-B1 | PROCESS FOR THE PREPARATION OF RILPIVIRINE | MINAKEM (FR) | 2023-06-28 | — | — | EP | disclosed |
| CN-111333543-B | Synthesis method of rilpivirine intermediate | 武汉工程大学 | 2022-09-16 | — | — | CN | disclosed |
| CN-111333543-B | Synthesis method of rilpivirine intermediate | 武汉工程大学 | 2022-09-16 | — | — | CN | disclosed |
| US-20210380540-A1 | PROCESS FOR THE PREPARATION OF RILPIVIRINE | MINAKEM (FR) | 2021-12-09 | — | — | US | disclosed |
| WO-2006035068-A2 | HIV INHIBITING 5-CARBO- OR HETEROCYCLIC SUBSTITUTED PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006035067-A2 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006015985-A1 | HIV INHIBITING 1,2,4-TRIAZIN-6-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-16 | — | — | WO | disclosed |
| CN-1681774-A | Process for the preparation of 4- [ [ 4- [ [ 4- (2-cyanoethenyl) -2, 6-dimethylphenyl ] amino ] -2-pyrimidinyl ] amino ] benzonitrile | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-12 | — | — | CN | disclosed |
| EP-1529032-A1 | PROCESSES FOR THE PREPARATION OF 4- 4- 4-(2 -CYANOETHENYL)-2,6-DIMETHYLPHENYL )AMINO) -2-PYRIMIDINYL)AMINO BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016581-A1 | PROCESSES FOR THE PREPARATION OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380540-A1 | PROCESS FOR THE PREPARATION OF RILPIVIRINE | CYP3A5, SAMHD1, IL5 | KDM4E 719/4885CYP3A4 22/4885ALDH1A1 1214/4885 |
| US-10590145-B2 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KDM4E 1931/4885CYP3A4 249/4885ALDH1A1 931/4885 |
| US-20200031844-A1 | Tetrahydrothiopyranopyrimidine derivatives as anti-HIV agent | TYMP, DPYD, TPMT | KDM4E 1931/4885CYP3A4 249/4885ALDH1A1 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.